ClinicalTrials.gg
RecruitingNCT05420259Updated Mar 19, 2024

Combined Exercise and Nutritional Intervention in GI Cancer Patients

An interventional study of Combined Exercise and Dietary Intervention (CEDI) and Standard Care in Pancreatic Cancer, Gastric Cancer and Diet, sponsored by Hospital Beatriz Ângelo. Recruiting at 2 sites in Portugal. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by Hospital Beatriz Ângelo · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Pancreatic Neoplasms with a site in Portugal — 3 open to participants now, 4 under way, none of them phase 3. Pancreatic Neoplasms · Portugal.

Planned enrollment
11th of 14
68 · median 145
Started
2022
the only one that year
No phase
5 of 17
2 open now
Registered
14th of 17
by date

Among the 17 studies in Pancreatic Neoplasms with a site in Portugal, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is one of 5 with no phase, and was the 14th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 17 studies in Pancreatic Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pancreatic Neoplasms with a site in Portugal, or all of them as a file.
02

Study summary

Although some studies have focused on the role of exercise on inflammation and cytokine expression in cancer patients undergoing treatment and survivors, to our knowledge none have investigated the effect of exercise during neoadjuvant treatment as a complementary therapy to 1) modulate inflammation which may have a positive influence on chemotherapy response and 2) preserve or improve skeletal muscle, thus preventing cancer cachexia. Furthermore, we believe that the neoadjuvant treatment period could be a window of opportunity to optimize patient's nutritional status before surgery, which until now has been under used.

Bearing in mind that nutritional interventions may also influence IL-6, our hypothesis is that a Combined Exercise and Dietary Intervention (CEDI) may induce positive alterations in cytokine profile and increase NK cell infiltration of the tumor in gastric and pancreatic cancer patients submitted to neo-adjuvant therapy.

03

Conditions studied

  • Pancreatic Cancer
  • Gastric Cancer
  • Diet
  • Exercise

Keywords

  • Body composition
  • Wasting
  • Malnutrition
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • gastric or pancreatic cancer stage II/III, eligible for chemotherapy,
  • age higher than 40 years and lower than 80 years,
  • (Eastern Cooperative Oncology Group) functional status: 0-2,
  • sedentary/low physical activity level.

Exclusion criteria

Exclusion Criteria:

  • less than 12 months at inclusion,
  • chemotherapy regimen other than 5-Fluorouracil, Folinic acid, Oxaliplatin, Docetaxel (FLOT) for gastric and 5-Fluorouracil, Irinotecan and Oxaliplatin (FOLFIRINOX) or gemcitabine for pancreatic cancer,
  • disease,
  • chronic anti-inflammatory medication use,
  • known inflammatory condition (rheumatoid arthritis, ankylosing spondylitis or chronic active hepatitis)
  • cardiovascular, respiratory or musculoskeletal or joint problems that preclude moderate physical activity.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Combined Exercise and Dietary Intervention

    Intervention aimed at conveying a supervised combined moderate aerobic and resistance training, once a week with a duration of 40-60 minutes plus daily home exercise, personalized according to patients' age and functional status. Dietary intervention aimed at a one-on-one nutritional counseling. In the first visit a dietary plan is designed and one daily oral nutritional supplement (Fortimel Compact®, Nutricia) is given to meet the European Society of Parenteral and Enteral Nutrition (ESPEN) recommended intake.

    Behavioral: Combined Exercise and Dietary Intervention (CEDI)

  • Other
    Control

    Standard Care

    Behavioral: Standard Care

Interventions

  • BehavioralCombined Exercise and Dietary Intervention (CEDI)

    The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.

  • BehavioralStandard Care

    Standard Care

06

What researchers measure

Primary outcomes

  1. Mean Change in interleukin 6 (IL6)

    IL6 circulating levels will be determined before and after combined exercise and dietary intervention (CEDI)

    Time frame: 8 weeks

Secondary outcomes

  1. Change in Immune cell infiltration profile on tumor specimen

    Peri-tumoral cell distribution (NK cells, T cells) will be determined before and after combined exercise and dietary intervention (CEDI)

    Time frame: 8 weeks

  2. Change in skeletal muscle

    Skeletal muscle using CT scan body composition analysis will be assessed before and after combined exercise and dietary intervention (CEDI)

    Time frame: 8 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jun 2024, 27 months after the start.

Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 27 months is below that.

Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2022
First posted
Jun 15, 2022
StartActual
Mar 21, 2022
Primary completionEst.
Jun 28, 2024
CompletionEst.
Jun 28, 2024
Last update
Mar 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05420259
Lead sponsor
Hospital Beatriz Ângelo
Responsible party
Sónia Velho (Nutricionist, Hospital Beatriz Ângelo) — Principal investigator
First posted
Jun 15, 2022
Start date
Mar 21, 2022
Primary completion
Jun 28, 2024 (estimated)
Completion
Jun 28, 2024 (estimated)
Last update
Mar 19, 2024

Study contacts

Sónia Velho
Contact
soniavelho0@gmail.com
+351914644141
Marilia Cravo
Contact
marilia.cravo@sapo.pt
919439192
Marilia Cravo
study director · Hospital da Luz

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion